CD40 ligand-dependent T cell activation: Requirement of B7-CD28 signaling through CD40

Science

Volumn 273, Issue 5283, 1996, Pages 1862-1864

  Yang, Yiping ^a   Wilson, James M ^a,b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; LIGAND; VIRUS VECTOR;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION REGULATION; GENE TRANSFER; HUMORAL IMMUNITY; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION;

EID: 0029780119     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.273.5283.1862     Document Type: Article

References (29)

1. R. Allen et al., Science 259, 990 (1993); A. Aruflo et al., Cell 72, 291 (1993); J. Disanto, J. Bonnefoy, J. Gauchel, A. Fischer, G. deSainte Basile, Nature 361, 541 (1993); U. Korthauer et al., ibid. p. 539; B. Renshaw et al., J. Exp. Med. 180, 1889 (1994); J. Xu et al., Immunity 1, 423 (1994).
2. R. Allen et al., Science 259, 990 (1993); A. Aruflo et al., Cell 72, 291 (1993); J. Disanto, J. Bonnefoy, J. Gauchel, A. Fischer, G. deSainte Basile, Nature 361, 541 (1993); U. Korthauer et al., ibid. p. 539; B. Renshaw et al., J. Exp. Med. 180, 1889 (1994); J. Xu et al., Immunity 1, 423 (1994).
3. R. Allen et al., Science 259, 990 (1993); A. Aruflo et al., Cell 72, 291 (1993); J. Disanto, J. Bonnefoy, J. Gauchel, A. Fischer, G. deSainte Basile, Nature 361, 541 (1993); U. Korthauer et al., ibid. p. 539; B. Renshaw et al., J. Exp. Med. 180, 1889 (1994); J. Xu et al., Immunity 1, 423 (1994).
4. R. Allen et al., Science 259, 990 (1993); A. Aruflo et al., Cell 72, 291 (1993); J. Disanto, J. Bonnefoy, J. Gauchel, A. Fischer, G. deSainte Basile, Nature 361, 541 (1993); U. Korthauer et al., ibid. p. 539; B. Renshaw et al., J. Exp. Med. 180, 1889 (1994); J. Xu et al., Immunity 1, 423 (1994).
5. R. Allen et al., Science 259, 990 (1993); A. Aruflo et al., Cell 72, 291 (1993); J. Disanto, J. Bonnefoy, J. Gauchel, A. Fischer, G. deSainte Basile, Nature 361, 541 (1993); U. Korthauer et al., ibid. p. 539; B. Renshaw et al., J. Exp. Med. 180, 1889 (1994); J. Xu et al., Immunity 1, 423 (1994).
6. R. Allen et al., Science 259, 990 (1993); A. Aruflo et al., Cell 72, 291 (1993); J. Disanto, J. Bonnefoy, J. Gauchel, A. Fischer, G. deSainte Basile, Nature 361, 541 (1993); U. Korthauer et al., ibid. p. 539; B. Renshaw et al., J. Exp. Med. 180, 1889 (1994); J. Xu et al., Immunity 1, 423 (1994).
7. I. Grewal, J. Xu, R. Flavell, Nature 378, 617 (1995); D. van Essen, H. Kikutani, D. Gray, ibid., p. 620.
8. I. Grewal, J. Xu, R. Flavell, Nature 378, 617 (1995); D. van Essen, H. Kikutani, D. Gray, ibid., p. 620.
9. K. Campbell et al., Immunity 4, 283 (1996); M. Kamanaka et al., ibid., p. 275; L. Soong et al., ibid., p. 263.
10. K. Campbell et al., Immunity 4, 283 (1996); M. Kamanaka et al., ibid., p. 275; L. Soong et al., ibid., p. 263.
11. K. Campbell et al., Immunity 4, 283 (1996); M. Kamanaka et al., ibid., p. 275; L. Soong et al., ibid., p. 263.
12. C. P. Larsen et al., Nature 381, 434 (1996).
13. Y. Dai et al., Proc. Natl. Acad. Sci. U.S.A. 92, 1401 (1995); Y. Yang, H. C. J. Ertl, J. M. Wilson, Immunity 1, 433 (1994); Q. Li, M. A. Kay, M. Finegold, L. D. Stratford-Perricaudet. S. L. C. Woo, Hum. Gene Ther. 4, 403 (1993); M. A. Rosenfeld et al., Cell 68, 143 (1992); Y. Yang, Q. Li, H. Ertl, J. Wilson, J. Virol. 69, 2004 (1995); Z. Zsengeller et al., Hum. Gene Ther. 6, 457 (1995).
14. Y. Dai et al., Proc. Natl. Acad. Sci. U.S.A. 92, 1401 (1995); Y. Yang, H. C. J. Ertl, J. M. Wilson, Immunity 1, 433 (1994); Q. Li, M. A. Kay, M. Finegold, L. D. Stratford-Perricaudet. S. L. C. Woo, Hum. Gene Ther. 4, 403 (1993); M. A. Rosenfeld et al., Cell 68, 143 (1992); Y. Yang, Q. Li, H. Ertl, J. Wilson, J. Virol. 69, 2004 (1995); Z. Zsengeller et al., Hum. Gene Ther. 6, 457 (1995).
15. Y. Dai et al., Proc. Natl. Acad. Sci. U.S.A. 92, 1401 (1995); Y. Yang, H. C. J. Ertl, J. M. Wilson, Immunity 1, 433 (1994); Q. Li, M. A. Kay, M. Finegold, L. D. Stratford-Perricaudet. S. L. C. Woo, Hum. Gene Ther. 4, 403 (1993); M. A. Rosenfeld et al., Cell 68, 143 (1992); Y. Yang, Q. Li, H. Ertl, J. Wilson, J. Virol. 69, 2004 (1995); Z. Zsengeller et al., Hum. Gene Ther. 6, 457 (1995).
16. Y. Dai et al., Proc. Natl. Acad. Sci. U.S.A. 92, 1401 (1995); Y. Yang, H. C. J. Ertl, J. M. Wilson, Immunity 1, 433 (1994); Q. Li, M. A. Kay, M. Finegold, L. D. Stratford-Perricaudet. S. L. C. Woo, Hum. Gene Ther. 4, 403 (1993); M. A. Rosenfeld et al., Cell 68, 143 (1992); Y. Yang, Q. Li, H. Ertl, J. Wilson, J. Virol. 69, 2004 (1995); Z. Zsengeller et al., Hum. Gene Ther. 6, 457 (1995).
17. Y. Dai et al., Proc. Natl. Acad. Sci. U.S.A. 92, 1401 (1995); Y. Yang, H. C. J. Ertl, J. M. Wilson, Immunity 1, 433 (1994); Q. Li, M. A. Kay, M. Finegold, L. D. Stratford-Perricaudet. S. L. C. Woo, Hum. Gene Ther. 4, 403 (1993); M. A. Rosenfeld et al., Cell 68, 143 (1992); Y. Yang, Q. Li, H. Ertl, J. Wilson, J. Virol. 69, 2004 (1995); Z. Zsengeller et al., Hum. Gene Ther. 6, 457 (1995).
18. Y. Dai et al., Proc. Natl. Acad. Sci. U.S.A. 92, 1401 (1995); Y. Yang, H. C. J. Ertl, J. M. Wilson, Immunity 1, 433 (1994); Q. Li, M. A. Kay, M. Finegold, L. D. Stratford-Perricaudet. S. L. C. Woo, Hum. Gene Ther. 4, 403 (1993); M. A. Rosenfeld et al., Cell 68, 143 (1992); Y. Yang, Q. Li, H. Ertl, J. Wilson, J. Virol. 69, 2004 (1995); Z. Zsengeller et al., Hum. Gene Ther. 6, 457 (1995).
19. Y. Yang, G. Trinchieri, J. M. Wilson, Nature Med. 1, 890 (1995).
20. M. A. Kay et al., Nature Genet. 11, 191 (1995).
21. Y. Yang et al., J. Virol. 70, 6370 (1996).
22. / mice were also treated with a monoclonal antibody to CD40 (anti-CD40) (100 μg/day, Pharmingen, San Diego, CA) for 7 days after immunization, and C57BL/6 mice were treated with monoclonal antibodies to B7.1 and B7.2 (100 μg/day; Pharmingen, San Diego, CA) every 3 days after immunization for the duration of the experiment.
23. 51 Cr release was calculated as follows: [(cpm of sample - cpm of spontaneous release)/(cpm of maximal release - cpm of spontaneous release)] × 100. Spontaneous release was determined by culturing target cells in medium, and maximal release was established by culturing target cells in a 1% solution of SDS. The percentage of specific lysis is expressed as a function of different effector-to-target ratios (6:1, 12:1, 25:1, and 50:1).
24. / mice treated with anti-CD40 and C57BL/6 mice treated with anti-B7.1 and anti-B7.2 were harvested 10 days after infusion of H5.010CMVlacZ virus, and the frozen sections were analyzed for germinal center formation. Frozen sections were fixed with methanol for 10 min at -2C°C, air-dried, and rehydrated with phosphate-buffered saline (PBS). After blocking with 10% goat serum for 20 min. sections were incubated with peanut agglutinin conjugated to fluorescein isothiocyanate (FITC) (Sigma; 20 μg/ml) for 1 hour at room temperature. Sections were washed and mounted with Citiflour (Canterbury, UK). Four spleen sections from two mice (2) were stained for the presence of germinal centers (GCs) and analyzed. Data are represented as the number of GCs per section (mean ± SD).
25. Y. Wu, Curr. Biol. 5, 1303 (1995).
26. J. Hasbold, C. Johnson-Leger, C. Atkins, E. Clark, G. Klaus, Eur. J. Immunol. 24, 1835 (1994).
27. J. Allison and M. Krummel, Science 270, 932 (1995).
28. Antiviral antibodies were evaluated with an ELISA assay in which microtiter plates were coated with 200 ng of viral antigen in 10 μl of PBS per well overnight at 4°C, washed three times in PBS, and blocked with 1% bovine serum albumin (BSA) in PBS for 1 hour at 37°C. Serum samples diluted 1:200 were added to antigen-coated plates and incubated for 4 hours at 37°C. Plates were washed three times with 0.05% Tween-20 in PBS and incubated with biotin-labeled goat antibody to mouse IgG1, IgG2a, or IgM (Pharmingen, San Diego, CA) at 1:1000 dilution overnight at 4°C. Plates were washed as above and anti-biotin phosphatase (Sigma) was added to each well at 1:30,000 dilution for 1 hour at 37°C. Wells were washed again as above and p-nitrophenyl phosphate substrate was added.
29. We thank the Vector Core and Clinical Pathology and Animal Service Units of the Institute for Human Gene Therapy for technical help. Supported by the National Institute of Diabetes and Digestive and Kidney Diseases of NIH, the Cystic Fibrosis Foundation, and Genovo, Inc., a company that J.M.W. founded and holds equity in.